MCMCB Pro
J2507

J2507Injection, pegloticase, 1 mg

HCPCSActiveBETOS O1E

J2507 is a HCPCS Level II code for injection, pegloticase, 1 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.

Medicare coverage: Carrier judgment

Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.

Physician fee schedule statusE

Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).

Global period: XXX

Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.

Medically Unlikely Edits — units per day

The most units of J2507 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.

practitioner
8 units
MAI 3 — Date of Service Edit: Clinical · Prescribing Information
outpatient
8 units
MAI 3 — Date of Service Edit: Clinical · Prescribing Information
DME supplier
0 — never payable
MAI 3 — Date of Service Edit: Clinical · CMS Policy

The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute — no documentation overrides it. CMS MUE 2026Q3.

The CMS record for J2507

Long descriptor
Injection, pegloticase, 1 mg

The official wording. This is what the code means.

Short descriptor
Pegloticase injection

CMS's 28-character form, which is what shows up on a remittance advice.

Added
January 1, 2012

When CMS introduced the code.

BETOS
O1E

Berenson-Eggers Type of Service — CMS's own analytic grouping.

Pricing indicator
51 — Other

Drugs.

Codes adjacent to J2507

HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J2507 is not quite right, the correct code is very often within a few positions of it.

  • J2471Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg
  • J2472Injection, pantoprazole sodium in sodium chloride (baxter), 40 mg
  • J2501Injection, paricalcitol, 1 mcg
  • J2502Injection, pasireotide long acting, 1 mg
  • J2503Injection, pegaptanib sodium, 0.3 mgterminated
  • J2504Injection, pegademase bovine, 25 iuterminated
  • J2505Injection, pegfilgrastim, 6 mgterminated
  • J2506Injection, pegfilgrastim, excludes biosimilar, 0.5 mg
  • J2508Injection, pegunigalsidase alfa-iwxj, 1 mg
  • J2510Injection, penicillin g procaine, aqueous, up to 600,000 units
  • J2513Injection, pentastarch, 10% solution, 100 mlterminated
  • J2515Injection, pentobarbital sodium, per 50 mg
  • J2516Injection, pentamidine isethionate, 1 mg
  • J2540Injection, penicillin g potassium, up to 600,000 units
  • J2543Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams)
  • J2545Pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg

Questions about J2507

What is HCPCS code J2507?

J2507 is a HCPCS Level II code for injection, pegloticase, 1 mg. It sits in the Drugs Administered Other Than Oral Method section.

Does Medicare cover J2507?

The CMS HCPCS file marks J2507 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.

How is J2507 paid under the physician fee schedule?

J2507 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).

HCPCS Level II2026Q3-Jul· effective July 1, 2026